Comments

Ligand Pharmaceuticals Stock Guidance

LGNDNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
Q4 2024 Earnings were released on Thu Feb 27th, before the market open
The most recent conference call was at 8:30 AM, 5 days ago Click to view past webcast
Ligand Pharmaceuticals (LGND) ForecastNewsEarningsLigand Pharmaceuticals (LGND) Options

Guidance

DividendsAnalyst RatingsInsider TradesShort Interest

Ligand Pharmaceuticals Stock Guidance | NASDAQ:LGND | Benzinga

Ligand Pharmaceuticals issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Data brought to you by Benzinga APIs

FAQ

Q

What is the most recent guidance for Ligand Pharmaceuticals (LGND)?

A

The most recent guidance for Ligand Pharmaceuticals (LGND) was reported on February 27, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $6.00 to $6.25, compared to the estimated EPS of $6.14. Additionally, Ligand Pharmaceuticals forecasted revenue between $0.18B and $0.20B for the quarter.

Browse guidance and forecast on all stocks.

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved